Cargando…

Comparison of the structure-function properties of wild-type human apoA-V and a C-terminal truncation associated with elevated plasma triglycerides

BACKGROUND: Plasma triglycerides (TGs) are causally associated with coronary artery disease and acute pancreatitis. Apolipoprotein A-V (apoA-V, gene APOA5) is a liver-secreted protein that is carried on triglyceride-rich lipoproteins and promotes the enzymatic activity of lipoprotein lipase (LPL), t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stankov, Sylvia, Vitali, Cecilia, Park, Joseph, Nguyen, David, Mayne, Leland, Englander, S. Walter, Levin, Michael G., Vujkovic, Marijana, Hand, Nicholas J., Phillips, Michael C., Rader, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980232/ https://www.ncbi.nlm.nih.gov/pubmed/36865344 http://dx.doi.org/10.1101/2023.02.21.23286268

Ejemplares similares

Comparison of apoA-I helical structure and stability in discoidal and spherical HDL particles by HX and mass spectrometry
por: Chetty, Palaniappan Sevugan, et al.
Publicado: (2013)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)

ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
por: Chen, Yan Q., et al.
Publicado: (2021)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

ApoA-1 in Diabetes: Damaged Goods
por: Ory, Daniel S., et al.
Publicado: (2010)

Insights into the fate of the N-terminal amyloidogenic polypeptide of ApoA-I in cultured target cells
por: Arciello, Angela, et al.
Publicado: (2011)

Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study
por: Ariza, María-José, et al.
Publicado: (2010)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

LCAT, ApoD, and ApoA1 Expression and Review of Cholesterol Deposition in the Cornea
por: Flores, Rhonda, et al.
Publicado: (2019)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

Influences of APOA5 Variants on Plasma Triglyceride Levels in Uyghur Population
por: Li, Shuyuan, et al.
Publicado: (2014)

Estrogen lowers triglyceride via regulating hepatic APOA5 expression
por: Luo, Fei, et al.
Publicado: (2017)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Clinical ApoA‐IV amyloid is associated with fibrillogenic signal sequence
por: Canetti, Diana, et al.
Publicado: (2021)

ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity()
por: Lu, Min, et al.
Publicado: (2011)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

A conserved strategy for structure change and energy transduction in Hsp104 and other AAA+ protein motors
por: Ye, Xiang, et al.
Publicado: (2021)

Correction: A conserved strategy for structure change and energy transduction in Hsp104 and other AAA+ protein motors
por: Ye, Xiang, et al.
Publicado: (2021)

Crystallization of ApoA1 and ApoE4 nanolipoprotein particles and initial XFEL-based structural studies
por: Shelby, M.L., et al.
Publicado: (2020)

Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction
por: Chen, Yan, et al.
Publicado: (2023)

Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome
por: Ng, Theodore W. K., et al.
Publicado: (2009)

ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid
por: Neufeld, Edward B., et al.
Publicado: (2019)

Association of serum apoA-I with in-stent restenosis in coronary heart disease
por: Wang, Xin, et al.
Publicado: (2022)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Prognosis evaluation of universal acute coronary syndrome: the interplay between SYNTAX score and ApoB/ApoA1
por: Wang, Xiaotong, et al.
Publicado: (2020)

Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease
por: Sorokin, Alexander V., et al.
Publicado: (2023)

ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
por: Kalayci, Arzu, et al.
Publicado: (2022)

APOA1-75 G to A Substitution Associated with Severe Forms of CAD, Lower Levels of HDL and apoA-I among Northern Indians
por: Chhabra, S., et al.
Publicado: (2005)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

Effect of apoA-I PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins
por: Pedersbæk, Dennis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bo0ltle3j5d4b8db7ejod0cjce